Jpmorgan Chase & CO Evelo Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.17 - $1.57 $66 - $617	393 Added 11.12%	3,927 $0
Q4 2022 Feb 13, 2023	SELL	$1.44 - $48.2 $5,290 - $177,086	-3,674 Reduced 50.97%	3,534 $6,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $41.8 $3,984 - $89,535	2,142 Added 42.28%	7,208 $15,000
Q2 2022 Aug 11, 2022	SELL	$1.46 - $3.55 $22,540 - $54,808	-15,439 Reduced 75.29%	5,066 $11,000
Q1 2022 May 11, 2022	BUY	$2.66 - $6.63 $11,145 - $27,779	4,190 Added 25.68%	20,505 $69,000
Q4 2021 Feb 10, 2022	BUY	$6.07 - $12.0 $28,419 - $56,184	4,682 Added 40.25%	16,315 $99,000
Q3 2021 Nov 12, 2021	BUY	$6.79 - $13.9 $78,988 - $161,698	11,633 New	11,633 $82,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.